New agents and regimens for diffuse large B cell lymphoma

• Published in: Journal of hematology and oncology Vol. 13; no. 1; pp. 175 - 23
• Main Authors: Wang, Liang, Li, Lin-Rong, Young, Ken H
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 14.12.2020; BioMed Central; BMC
• Subjects: Animals; Anthracyclines; Antibodies; Antigens; Antineoplastic Agents - pharmacology; Antineoplastic Agents - therapeutic use; Antineoplastic Agents, Immunological - pharmacology; Antineoplastic Agents, Immunological - therapeutic use; Antineoplastic Combined Chemotherapy Protocols - pharmacology; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; B-cell lymphoma; Biological products; Chemoresistance; Chimeric antigen receptor T cells; Chimeric antigen receptors; Classification systems; Clinical trials; Corticosteroids; Cyclophosphamide; Cytokines; Development and progression; Diffuse large B cell lymphoma; Disease resistance; Doxorubicin; Drug Development; Epigenesis, Genetic - drug effects; Epigenetics; FDA approval; Genetic classification; Hematology; Humans; Immune checkpoint inhibitors; Immune Checkpoint Inhibitors - pharmacology; Immune Checkpoint Inhibitors - therapeutic use; Immunoconjugates - pharmacology; Immunoconjugates - therapeutic use; Immunologic Factors - pharmacology; Immunologic Factors - therapeutic use; Immunomodulation; Immunosuppressive agents; Immunotherapy; Immunotherapy - methods; Leukemia; Lymphocytes; Lymphocytes T; Lymphoma; Lymphoma, Large B-Cell, Diffuse - genetics; Lymphoma, Large B-Cell, Diffuse - immunology; Lymphoma, Large B-Cell, Diffuse - metabolism; Lymphoma, Large B-Cell, Diffuse - therapy; Monoclonal antibodies; Neurotoxicity; Non-Hodgkin's lymphomas; Novel agents; Oncology; Prednisone; Review; Rituximab; Signal Transduction; T cells; Targeted cancer therapy; Tumors; Vincristine; Diffuse large B cell lymphoma; Novel agents; Chimeric antigen receptor T cells; Genetic classification; Immunotherapy; Chemoresistance
• ISSN: 1756-8722; 1756-8722
• DOI: 10.1186/s13045-020-01011-z

As a widely recognized standard regimen, R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone) is able to cure two-thirds patients with diffuse large B cell lymphoma (DLBCL), and the remaining patients suffer from refractory or relapsed disease due to resistance to R-CHOP and fare poorly. Unsatisfied outcomes for those relapsed/refractory patients prompted efforts to discover new treatment approaches for DLBCL, including chimeric antigen receptor T cells, bispecific T cell engagers, immunomodulatory drugs, immune checkpoint inhibitors, monoclonal antibodies, antibody-drug conjugates, molecular pathway inhibitors, and epigenetic-modifying drugs. Herein, up-to-date data about the most promising treatment approaches for DLBCL are recapitulated, and novel genetic classification systems are introduced to guide individualized treatment for DLBCL.